/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

SANA BIOTECHNOLOGY INC Share Price Today: Live Updates & Key Insights

SANA BIOTECHNOLOGY INC share price today is $3.13, up -1.9%. The stock opened at $3.15 against the previous close of $3.15, with an intraday high of $3.15 and low of $3.01.

SANA BIOTECHNOLOGY INC Share Price Chart

style
pb-0

SANA BIOTECHNOLOGY INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

SANA BIOTECHNOLOGY INC Share Price Performance

$3.13 -0.019(-1.9%) SANA at 13 Mar 2026 03:07 PM Biotechnology
Lowest Today 3.01
Highest Today 3.15
Today’s Open 3.15
Prev. Close 3.15
52 Week High 6.55
52 Week Low 1.26
Day’s Range: Low 3.01 High 3.15
52-Week Range: Low 1.26 High 6.55
1 day return -
1 Week return -1.27
1 month return -19.37
3 month return -39.03
6 month return -4.17
1 year return +16.76
3 year return -10.91
5 year return -89.43
10 year return -

SANA BIOTECHNOLOGY INC Institutional Holdings

FMR Inc 14.03

Flagship Ventures Management, Inc. 9.37

Fidelity Growth Compy Commingled Pl S 5.65

BlackRock Inc 4.21

Fidelity Growth Company Fund 3.94

Vanguard Group Inc 3.92

Canada Pension Plan Investment Board 3.84

State Street Corp 2.50

Baillie Gifford & Co Limited. 2.48

Scottish Mortgage Ord 2.47

Citadel Advisors Llc 2.46

Vanguard Total Stock Mkt Idx Inv 2.04

State Street® SPDR® S&P® Biotech ETF 1.70

JPMorgan Chase & Co 1.60

iShares Russell 2000 ETF 1.49

Marex Group PLC 1.43

Geode Capital Management, LLC 1.28

Fidelity Growth Company K6 1.18

Fidelity Series Growth Company 1.07

Alphabet Inc 1.05

Integral Health Asset Management, LLC 0.75

Vanguard Institutional Extnd Mkt Idx Tr 0.66

Renaissance Technologies Corp 0.63

Balyasny Asset Management LLC 0.63

Fidelity Small Cap Index 0.61

Millennium Management LLC 0.61

Two Sigma Investments LLC 0.59

UBS Group AG 0.54

Charles Schwab Investment Management Inc 0.52

Northern Trust Corp 0.49

iShares Russell 2000 Value ETF 0.48

Fidelity Select Biotechnology 0.47

iShares Biotechnology ETF 0.47

State St Russell Sm/Mid Cp® Indx SL Cl I 0.36

Fidelity Extended Market Index 0.32

Vanguard Russell 2000 ETF 0.29

Schwab US Small-Cap ETF™ 0.29

JPM Thematics Genetic Thrps C2 dist USD 0.27

State St Russell Sm Cap® Indx SL Cl I 0.20

Vanguard Health Care ETF 0.19

SANA BIOTECHNOLOGY INC Market Status

Strong Buy: 4

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

SANA BIOTECHNOLOGY INC Fundamentals

Market Cap 840.63 M

PB Ratio 5.2251

PE Ratio 0.0

Enterprise Value 781.11 M

Total Assets 416.89 M

Volume 3748035

SANA BIOTECHNOLOGY INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-275581000 -275.6M, FY22:-266388000 -266.4M, FY21:-344182000 -344.2M, FY20:-278637000 -278.6M, FY19:-130778000 -130.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-2857000 -2.9M, Q1/2025:-3649000 -3.6M, Q3/2024:null 0.0M, Q2/2024:-3895000 -3.9M

Quarterly Net worth Q3/2025:-42152000 -42.2M, Q2/2025:-93800000 -93.8M, Q1/2025:-49389000 -49.4M, Q3/2024:-59924000 -59.9M, Q2/2024:-50291000 -50.3M

About SANA BIOTECHNOLOGY INC & investment objective

Company Information Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Organisation Biotechnology

Employees 142

Industry Biotechnology

CEO Dr. Steven D. Harr M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow